Article
Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Future oncology (London, England) - 1 Mar 2021
Solomon Benjamin J, Zhou Cai Cun, Drilon Alexander, Park Keunchil, Wolf Jürgen, Elamin Yasir, Davis Hannah M, Soldatenkova Victoria, Sashegyi Andreas, Lin Aimee Bence, Lin Boris K, F Loong Herbert H, Novello Silvia, Arriola Edurne, Pérol Maurice, Goto Koichi, Santini Fernando C
Abstract excerpt
Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.